ENLIVEN THERAPEUTICS INC (ELVN) Stock Price, Forecast & Analysis
USA - NASDAQ:ELVN - US29337E1029 - Common Stock
ELVN Key Statistics, Chart & Performance
The current stock price of ELVN is 17.63 USD. In the past month the price decreased by -15.32%. In the past year, price decreased by -39.12%.
ELVN Latest News, Press Relases and Analysis
ELVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.78 | 3.97B |
Related stock screener links
About ELVN
Company Profile
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 63 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Company Info
ENLIVEN THERAPEUTICS INC
6200 Lookout Road
Boulder COLORADO US
Employees: 63
Phone: 17206478519
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What does ELVN do?
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 63 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Can you provide the latest stock price for ENLIVEN THERAPEUTICS INC?
The current stock price of ELVN is 17.63 USD. The price decreased by -3.66% in the last trading session.
Does ENLIVEN THERAPEUTICS INC pay dividends?
ELVN does not pay a dividend.
How is the ChartMill rating for ENLIVEN THERAPEUTICS INC?
ELVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ENLIVEN THERAPEUTICS INC (ELVN)?
ENLIVEN THERAPEUTICS INC (ELVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
What is the Short Interest ratio of ENLIVEN THERAPEUTICS INC (ELVN) stock?
The outstanding short interest for ENLIVEN THERAPEUTICS INC (ELVN) is 13.92% of its float.
ELVN Technical Analysis
ELVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELVN. No worries on liquidiy or solvency for ELVN as it has an excellent financial health rating, but there are worries on the profitability.
ELVN Financial Highlights
Over the last trailing twelve months ELVN reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -3.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.89% | ||
| ROE | -20.52% | ||
| Debt/Equity | 0 |
ELVN Forecast & Estimates
16 analysts have analysed ELVN and the average price target is 41.48 USD. This implies a price increase of 135.28% is expected in the next year compared to the current price of 17.63.